Physician profile
John W Fox
NPI 1841587920
$103,807.06
in general payments reported to CMS, 2019-2025
13 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,925 · 2021: $19K · 2022: $30K · 2023: $13K · 2024: $15K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $7,253 · Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,280.00 |
| Travel and Lodging | $7,252.77 |
| Food and Beverage | $2,062.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $72,307.38 | 2021-2025 | |
| Ge Healthcare | $6,981.07 | 2022-2023 | |
| Celgene Corporation | $6,536.02 | 2019 | |
| Gilead Sciences, INC. | $6,480.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $2,750.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $2,320.00 | 2021 | |
| Biogen, INC. | $1,925.00 | 2020 | |
| Vifor Pharma, INC. | $1,512.50 | 2022 | |
| Genzyme Corporation | $1,041.00 | 2021 | |
| Boehringer Ingelheim International Gmbh | $1,032.35 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $875.00 | 2019 | |
| Shockwave Medical, INC | $29.81 | 2025 | |
| Inari Medical, INC. | $16.93 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.